Skip to content
Screener

Cogent Biosciences, Inc. COGT Financing Cash Flow

Financing Cash Flow at other companies

Pfizer logo
PfizerPFE
-$2.86B+45.4%
Amgen logo
AmgenAMGN
-$1.48B+44.6%
Incyte logo
IncyteINCY
$65.46M+682%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$79.85M+3,992,200%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$323.74M
Arcus Biosciences logo
Arcus BiosciencesRCUS
$16M-69.2%

Other financials

Income statement

See full
Operating income-$103.6M-38.3%
Net income-$97.4M-35.2%
EPS (diluted)-$0.53-1.9%

Balance sheet

See full
Cash & equivalents$241.2M+91.4%
Total debt$15.5M-9.4%
Total equity$607.7M+177%
Total assets$903.0M+218%

Cash flow

See full
Operating cash flow-$86.9M-30.6%
CapEx$449.0K-17.9%
Free cash flow-$87.3M-30.2%

Valuation

See full
Market cap$7.14B+366%
Enterprise value$6.92B+372%

Profitability

See full
Operating margin-1,044.3%
Net margin-950.4%
FCF margin-184.7%

Returns & leverage

See full
Return on equity-85.7%+1.7pp
Debt / equity-0.1×
Current ratio15.1×+10.0×

Where this comes from

Reported directly by Cogent Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 8:21 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-205170
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from pre-funded warrant exercises6
Proceeds from issuance of common stock upon stock option exercises5,756136
Proceeds from issuance of common stock from Employee Stock Purchase Plan1,062584
Net cash provided by financing activities52,53624,970
Net (decrease) increase in cash, cash equivalents and restricted cash(70,804)27,838
Cash, cash equivalents and restricted cash at beginning of period312,42898,165
Cash, cash equivalents and restricted cash at end of period$241,624$126,003
Supplemental disclosure of noncash investing and financing information:

Item 1. Financial Statements (Unaudited)

FAQ

What is Cogent Biosciences, Inc.'s financing cash flow?
Cogent Biosciences, Inc. (COGT) reported financing cash flow of $52.54M in Q1 2026.
How has Cogent Biosciences, Inc.'s financing cash flow changed year-over-year?
Cogent Biosciences, Inc.'s financing cash flow increased by 110.4% year-over-year, from $24.97M to $52.54M.
What is the long-term trend for Cogent Biosciences, Inc.'s financing cash flow?
Over 3 years (2022 to 2025), Cogent Biosciences, Inc.'s financing cash flow has grown at a 75.1% compound annual growth rate (CAGR), from $163.56M to $878.23M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Cogent Biosciences, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude